ACADIA Pharmaceuticals Inc. vs KLA Corp. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while KLA Corp. trades at $204.94 (market cap $261.92B). The key difference: KLA Corp. is far larger — about 51.7× ACADIA Pharmaceuticals Inc.'s market cap, and KLA Corp. pays a 0.46% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | KLAC | |
|---|---|---|
Market Cap | $5.07B | $261.92B |
Sector | Health | Technology |
52-Week High | $29.41 | $301.71 |
52-Week Low | $20.06 | $84.39 |
Enterprise Value | $4.19B | $263.17B |
Dividend Yield | — | 0.46% |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →